Skip to main content

TERUMO GLOBAL

Search

Select Region

Show — Select Region Hide — Select Region

- Regions/Countries
  - - Europe
    - Latin America
      - Mexico
        
        Brazil
        
        Colombia
        
        Chile and Argentina
  - - Asia Pacific
    - Australia
    - Korea
    - Vietnam
    - China
    - India
- Global Business website

About Terumo
About Terumo
Dear Stakeholders
Who We Are
Corporate Governance
Compliance
Regulations and Standards
Procurement Activity
At a Glance
Terumo Group Identity
Leadership Team
History
TERUMO’s Purpose
Terumo's Response to COVID-19
Business Overview
Business Overview
TIS Division (Terumo Interventional Systems)
Neurovascular Division (MicroVention)
Cardiovascular Division (Terumo Cardiovascular)/ HeartSheet Division
Vascular Graft Division (Terumo Aortic)
Hospital Care Solutions Division
Life Care Solutions Division
Pharmaceutical Solutions Division
Terumo Blood and Cell Technologies Company (Terumo Blood and Cell Technologies)
Sustainability
Sustainability
Sustainability News
Message from Top Management
Sustainability at the Terumo Group
Resolving Healthcare Challenges
Creating a Diverse and Inclusive Workplace
Reducing Environmental Footprint
Serving Our Communities
Report Library
GRI Standards Index
Technology
Technology
From Devices to Solutions
Basic Information
Basic Information Top
Research and Development
Production and Supply
Intellectual Property
Terumo Fellows
Stories - Our Technologies
Investors
Investors
Management Policy
Management Policy
Top Management Message
Business Risks
Disclaimer
IR Policy
Financial Highlights
IR Library
IR Library
Financial Statements
Presentations
Consolidated Financial Statements
Terumo Reports
IR Events
Shareholders & Stock
Shareholders Meeting
Stock Information
Shareholder Return
Credit Ratings and Corporate Bond
Analyst Coverage
Articles of Incorporation
Site Quote
IR Inquiries
News
News
May 25, 2023
Corporate
Terumo Blood and Cell Technologies Optimizing Cell Therapy Production Through Industry’s First Apheresis Training for Cell Therapy Manufacturers
Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia® Apheresis System at major conferences
May 15, 2023
Corporate
Terumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Company
52.2 Billion JPY Capital Investment to Strengthen the Production Capability to Meet the Growing Global Demands
May 15, 2023
Corporate
Terumo Appoints the Candidates for Directors (PDF 96.39 KB)
Global Network
Global Network
Japan
North America
South America
Europe, Middle East and Africa
Greater China
Asia and Pacific

Breadcrumb

Home
Investors
IR Library
Consolidated Financial Statements

Consolidated Financial Statements

Move to top

Top

FYE 3/2022
FYE 3/2020
FYE 3/2019
FYE 3/2018
FYE 3/2017

FYE 3/2022

Consolidated Financial Statements (PDF 1.19 MB)

Consolidated Financial Statements (PDF 1.19 MB)
FYE 3/2020

Consolidated Financial Statements (PDF 1.48 MB)
FYE 3/2019

Consolidated Financial Statements (PDF 1.52 MB)
FYE 3/2018

Consolidated Financial Statements (PDF 1.77 MB)
FYE 3/2017

Consolidated Financial Statements (PDF 2.93 MB)

Adobe Reader (free) is required to view PDF files.

Download Adobe Reader

Footer Menu

Show — Footer Menu Hide — Footer Menu

- Investors
- News
  - - News
    - Press Inquiries
- Global Network

About Terumo
Business Overview
Sustainability
Technology
Investors
News
Global Network

Footer

Show — Footer Hide — Footer

Terms and Conditions of Use
Privacy Policy
Cookie Policy
Cookie Settings
Social Media Policy
Site Map

Copyright © 2023 Terumo Corporation, All Rights Reserved.